Table 3

Age-adjusted and multivariate-adjusteda ORs and 95% CIs for breast cancer in relation to log-transformed serum organochlorine levels adjustedb for serum lipid levels among breast cancer cases and controls, Long Island Breast Cancer Study Project, 1996–1997

Organochlorine compoundQuintile cutpoints (ng/gm lipid)Cases, nControls, nAge-adjustedMultivariate-adjusteda
OR(95% CI)OR(95% CI)
DDE<306.91122841.001.00
306.91–515.00110830.84(0.56–1.26)0.88(0.58–1.32)
515.01–798.24127840.91(0.60–1.36)0.94(0.63–1.43)
798.25–1,373.48123850.82(0.54–1.25)0.92(0.60–1.42)
1,373.49–11,818.78150830.95(0.62–1.46)1.20(0.76–1.90)
DDT<44.79129811.001.00
44.79–61.4396820.72(0.48–1.08)0.69(0.44–1.07)
61.44–81.20123820.94(0.63–1.39)1.04(0.66–1.63)
81.21–108.03134821.00(0.67–1.48)1.16(0.75–1.80)
108.03–747.92133820.97(0.66–1.44)1.15(0.74–1.79)
Peak-4 PCBs<262.57134831.001.00
262.58–325.56112830.76(0.51–1.14)0.76(0.51–1.15)
325.57–427.78132830.87(0.58–1.29)0.90(0.60–1.35)
427.79–586.74123830.77(0.51–1.15)0.82(0.54–1.24)
583.74–3,287.34126830.72(0.47–1.10)0.83(0.54–1.29)
BZ118<32.66134831.001.00
32.66–46.45133830.96(0.65–1.41)0.96(0.64–1.42)
46.46–63.39109830.74(0.50–1.11)0.77(0.52–1.16)
63.40–94.94114830.72(0.48–1.09)0.82(0.54–1.24)
94.95–1,015.88136830.79(0.52–1.20)0.93(0.60–1.43)
BZ138<49.38117821.001.00
49.38–81.09153831.24(0.84–1.84)1.26(0.85–1.88)
81.10–111.15129831.00(0.67–1.49)1.04(0.69–1.55)
111.16–156.22106830.79(0.52–1.19)0.80(0.52–1.21)
156.23–936.75120830.83(0.54–1.26)0.96(0.63–1.48)
BZ153<103.75140821.001.00
103.75–130.02115830.74(0.50–1.10)0.75(0.50–1.13)
130.03–170.81132830.84(0.56–1.24)0.85(0.57–1.27)
170.82–227.54107830.64(0.43–0.97)0.68(0.45–1.03)
227.55–1,130.08132830.75(0.50–1.13)0.86(0.56–1.32)
BZ180<51.49123821.001.00
51.49–69.70121830.89(0.60–1.33)0.87(0.58–1.31)
69.71–87.41117830.83(0.55–1.24)0.81(0.54–1.23)
87.42–120.37128830.88(0.58–1.32)0.89(0.58–1.34)
120.38–721.29134830.86(0.56–1.31)0.95(0.62–1.46)
Chlordane<62.47109781.001.00
62.48–85.6899780.84(0.55–1.28)0.88(0.57–1.35)
85.69–111.42107780.89(0.59–1.36)0.97(0.64–1.49)
111.43–162.47145781.12(0.74–1.70)1.20(0.78–1.84)
162.48–473.08126780.88(0.56–1.37)0.98(0.62–1.55)
Dieldrin<14.9637291.001.00
14.97–20.9038271.10(0.55–2.19)1.19(0.59–2.41)
20.91–26.6732290.87(0.43–1.75)0.91(0.45–1.84)
26.68–33.4522280.62(0.30–1.30)0.64(0.30–1.35)
33.46–179.2946291.28(0.65–2.52)1.37(0.69–2.72)
  • a DDE, Peak-4 PCB, and individual PCB analyses were adjusted for age, race, history of fertility problems, and history of benign breast disease. Chlordane analyses were adjusted for age, race, history of fertility problems, and gravidity. DDT analyses were adjusted for history of benign breast disease, history of fertility problems, gravidity, and race. Dieldrin analyses were adjusted for age and race.

  • b Adjusted using method 2 as described by Phillips et al. (50) .